(Q56786182)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

16 June 2024

Claudia P Cortés

2

0 references

Marcelo Wolff

object named as

Marcelo J Wolff

1

0 references

author name string

Marcelo J. Wolff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

16 June 2024

Claudia P. Cortés

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

16 June 2024

Bryan E. Shepherd

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

16 June 2024

Carlos J. Beltrán

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

16 June 2024

Chilean AIDS Cohort Study Group

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683194

Journal of Acquired Immune Deficiency Syndromes

16 June 2024

language of work or name

English

0 references

publication date

November 2010

0 references

published in

0 references

volume

55

0 references

issue

3

0 references

page(s)

368-374

0 references

cites work

The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country--organization and preliminary results

1

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Using existing health care systems to respond to the AIDS epidemic: research and recommendations for Chile

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America

16 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

16 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

16 June 2024

11

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Five-year outcomes of the China National Free Antiretroviral Treatment Program

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CP

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load

16 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study).

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

16 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean

16 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

16 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis

16 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD).

16 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Sex differences in HIV-1 viral load and progression to AIDS.

16 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Antiretroviral therapy in a thousand patients with AIDS in Haiti

16 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia

16 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country

16 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings

16 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Antiretroviral adherence in a resource-poor setting

16 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Adherence to HAART and its principal determinants in a cohort of Senegalese adults

16 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India

16 June 2024

38

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa

16 June 2024

39

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

16 June 2024

40

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings

16 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB4FB9

16 June 2024

Identifiers

0 references